154.9 -4.99 (-3.12%) | 02-11 18:06 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 208.43 ![]() |
1-year : | 226.07 |
Resists | First : | 178.45 ![]() |
Second : | 193.55 |
Pivot price | 163.79 ![]() |
|||
Supports | First : | 154 ![]() |
Second : | 128.13 ![]() |
MAs | MA(5) : | 162.14 ![]() |
MA(20) : | 165.4 ![]() |
MA(100) : | 187.6 ![]() |
MA(250) : | 211.1 ![]() |
|
MACD | MACD : | -5.9 ![]() |
Signal : | -5.9 ![]() |
%K %D | K(14,3) : | 18.9 ![]() |
D(3) : | 31 ![]() |
RSI | RSI(14): 30.1 ![]() |
|||
52-week | High : | 275 | Low : | 154 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CRL ] has closed below the lower bollinger band by 19.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 52.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 158.81 - 159.76 | 159.76 - 160.47 |
Low: | 151.75 - 153 | 153 - 153.94 |
Close: | 153.25 - 155.1 | 155.1 - 156.48 |
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Tue, 11 Feb 2025
Charles River Laboratories International, Inc. (CRL) Expands AI-Powered Digital Pathology Collaboration with Deciphex - Insider Monkey
Tue, 11 Feb 2025
10 AI News Updates on Wall Street’s Radar - Insider Monkey
Tue, 11 Feb 2025
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions - BioSpace
Tue, 11 Feb 2025
Charles River's Game-Changing AI Partnership Revolutionizes Drug Safety Testing - What This Means for Pharma - StockTitan
Tue, 11 Feb 2025
Cambiar Investors LLC Sells 5,880 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NYSE
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Diagnostics & Research
|
|
Shares Out | 51 (M) |
Shares Float | 51 (M) |
Held by Insiders | 0.9 (%) |
Held by Institutions | 102.6 (%) |
Shares Short | 2,160 (K) |
Shares Short P.Month | 2,140 (K) |
EPS | 8.01 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 73.97 |
Profit Margin | 10.4 % |
Operating Margin | 14.6 % |
Return on Assets (ttm) | 4.8 % |
Return on Equity (ttm) | 11.9 % |
Qtrly Rev. Growth | -1.7 % |
Gross Profit (p.s.) | 28.54 |
Sales Per Share | 79.38 |
EBITDA (p.s.) | 18.55 |
Qtrly Earnings Growth | -21.3 % |
Operating Cash Flow | 796 (M) |
Levered Free Cash Flow | 495 (M) |
PE Ratio | 19.33 |
PEG Ratio | 0 |
Price to Book value | 2.09 |
Price to Sales | 1.95 |
Price to Cash Flow | 9.94 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |